drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (anti-CD20) immunosuppressant
drug_description
Chimeric anti-CD20 monoclonal antibody used to deplete CD20+ B cells (including memory B cells) to reduce new anti-HLA antibody formation before transplant.
nci_thesaurus_concept_id
C1702
nci_thesaurus_preferred_term
Rituximab
nci_thesaurus_definition
A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)
drug_mesh_term
Rituximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric anti-CD20 monoclonal IgG1 that binds CD20 on pre‑B and mature B lymphocytes, triggering complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity and inducing apoptosis, thereby depleting CD20+ B cells (including memory B cells) to reduce new anti-HLA antibody formation.
drug_name
Rituximab
nct_id_drug_ref
NCT06362967